BioCardia/ US09060U6064 /
| 6/14/2024 8:17:48 PM | Chg. -0.14 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 3.55USD | -3.79% | 264 Turnover: 907.53 |
-Bid Size: - | -Ask Size: - | 3.55 | 3.41 |
GlobeNewswire
6/7
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to ...
GlobeNewswire
5/9
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
GlobeNewswire
5/1
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in...
GlobeNewswire
4/25
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Isch...
GlobeNewswire
3/27
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
GlobeNewswire
3/20
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
GlobeNewswire
3/12
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart ...
GlobeNewswire
3/4
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial,...
GlobeNewswire
2/8
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved ...
GlobeNewswire
1/3
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Share...
GlobeNewswire
12/19/2023
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchym...
GlobeNewswire
12/18/2023
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical ...
GlobeNewswire
11/29/2023
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemi...
GlobeNewswire
11/16/2023
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market und...
GlobeNewswire
11/14/2023
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy f...
GlobeNewswire
11/8/2023
BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
GlobeNewswire
11/1/2023
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
GlobeNewswire
10/11/2023
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP H...
GlobeNewswire
9/6/2023
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
GlobeNewswire
9/5/2023
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failur...
GlobeNewswire
3/24/2022
BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022
